Shanghai Kindly Medical Instruments Co., Ltd. Class H (HK:1501)
:1501
Want to see HK:1501 full AI Analyst Report?
Top Page
Shanghai Kindly Medical Instruments Co., Ltd. Class H
(1501)
Select Model
Select Model
Rating:69Neutral
Price Target:
HK$34.00
â–²(16.04% Upside)
Action:Reiterated
Date:04/25/26
The score is driven primarily by solid underlying financial performance (growth and strong 2025 cash flow rebound) tempered by higher leverage and margin compression. Technicals add support with price above major moving averages and positive momentum, while valuation is only moderate given the ~20.8 P/E and no dividend yield data.
Positive Factors
Recurring consumables model
A business focus on disposable medical consumables creates recurring, procedure-linked revenue that is less cyclical than capital equipment. That durable revenue base supports steadier sales, inventory replenishment cycles, and predictable customer relationships over the next 2-6 months and beyond.
Negative Factors
Rising leverage
A large step-up in debt materially reduces balance-sheet flexibility and raises interest and refinancing risk. Higher leverage increases sensitivity to earnings volatility and can constrain strategic choices (M&A, capex, dividend policy) if operating cash flow weakens in the next 2-6 months.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring consumables model
A business focus on disposable medical consumables creates recurring, procedure-linked revenue that is less cyclical than capital equipment. That durable revenue base supports steadier sales, inventory replenishment cycles, and predictable customer relationships over the next 2-6 months and beyond.
Read all positive factors
Shanghai Kindly Medical Instruments Co., Ltd. Class H (1501) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$6.48B
Dividend YieldN/A
Average Volume (3M)29.01K
Price to Earnings (P/E)22.0
Beta (1Y)<0.01
Revenue Growth25.24%
EPS Growth7.29%
CountryHK
Employees1,735
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)1.21
Shares Outstanding211,200,000
10 Day Avg. Volume19,260
30 Day Avg. Volume29,013
Financial Highlights & Ratios
PEG Ratio1.47
Price to Book (P/B)2.35
Price to Sales (P/S)4.40
P/FCF Ratio16.87
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.39
Revenue Forecast (FY)HK$1.23B
Shanghai Kindly Medical Instruments Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Shanghai Kindly Medical Instruments Co., Ltd., founded in 2006 and based in Shanghai, China, focuses on the research, development, production, and international sales of cardiovascular interventional medical devices. The company's products reach c...
How the Company Makes Money
The company makes money primarily by selling its medical devices and disposable medical consumables to healthcare providers and distributors, generating revenue from product sales. Its revenue model typically includes: (1) domestic and potentially...
Shanghai Kindly Medical Instruments Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
67
Positive
Cash Flow
61
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.07B | 851.95M | 752.84M | 585.88M | 464.68M |
| Gross Profit | 636.79M | 537.66M | 438.07M | 332.49M | 275.75M |
| EBITDA | 353.06M | 255.43M | 225.88M | 159.99M | 168.81M |
| Net Income | 218.79M | 191.91M | 156.46M | 131.71M | 142.96M |
Balance Sheet | |||||
| Total Assets | 3.13B | 2.26B | 2.03B | 1.83B | 1.62B |
| Cash, Cash Equivalents and Short-Term Investments | 630.81M | 554.51M | 434.40M | 528.27M | 640.55M |
| Total Debt | 716.26M | 243.69M | 94.78M | 48.83M | 13.40M |
| Total Liabilities | 1.04B | 473.39M | 351.25M | 273.23M | 183.63M |
| Stockholders Equity | 2.00B | 1.77B | 1.65B | 1.51B | 1.40B |
Cash Flow | |||||
| Free Cash Flow | 278.17M | 59.80M | -53.05M | -62.75M | -205.07M |
| Operating Cash Flow | 340.98M | 225.54M | 178.15M | 180.46M | 72.76M |
| Investing Cash Flow | -491.99M | -187.31M | -283.81M | -316.18M | -268.08M |
| Financing Cash Flow | 263.40M | 56.97M | 8.06M | 9.72M | -31.07M |
Shanghai Kindly Medical Instruments Co., Ltd. Class H Technical Analysis
Negative
29.30
Price Trends
34.91
Negative
33.13
Negative
31.91
Negative
Market Momentum
-1.00
Negative
40.64
Neutral
24.24
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1501, the sentiment is Negative. The current price of 29.3 is below the 20-day moving average (MA) of 31.47, below the 50-day MA of 34.91, and below the 200-day MA of 31.91, indicating a bearish trend. The MACD of -1.00 indicates Negative momentum. The RSI at 40.64 is Neutral, neither overbought nor oversold. The STOCH value of 24.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1501.
Shanghai Kindly Medical Instruments Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | HK$5.46B | 9.29 | 16.76% | 3.65% | 11.07% | 48.01% | |
77 Outperform | HK$3.20B | 9.76 | 10.20% | 2.70% | 9.88% | 5.65% | |
69 Neutral | HK$6.48B | 21.99 | 11.30% | ― | 25.24% | 7.29% | |
67 Neutral | HK$1.63B | 15.58 | 3.68% | 7.46% | 7.11% | -34.66% | |
66 Neutral | HK$11.45B | 70.86 | 4.01% | ― | ― | ― | |
62 Neutral | HK$14.02B | 7.68 | 6.64% | 4.58% | 2.34% | -22.25% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:1501
Shanghai Kindly Medical Instruments Co., Ltd. Class H
30.68
5.93
23.94%
HK:1066
Shandong Weigao Group Medical Polymer Co
3.10
-2.78
-47.24%
HK:1358
PW Medtech Group Ltd.
1.13
-0.10
-8.06%
HK:3600
Modern Dental Group Limited
5.85
1.78
43.73%
HK:6699
Angelalign Technology Inc.
67.00
14.52
27.67%
HK:6929
OrbusNeich Medical Group Holdings Limited
3.89
0.15
3.87%
Shanghai Kindly Medical Instruments Co., Ltd. Class H Corporate Events
Shanghai INT Details Valuation and Compliance for Pulin Medical Stake Acquisition
Jun 25, 2026
Shanghai INT Medical Instruments Co., Ltd. has provided further details on its planned acquisition of a 35% equity stake in its non-wholly owned subsidiary, Shanghai Pulin Medical Instruments Co., Ltd., reinforcing its strategic focus on consolida...
Shanghai INT Medical Instruments Raises Stake in Target Company via Second Discloseable Acquisition
Jun 25, 2026
Shanghai INT Medical Instruments has agreed to further increase its stake in a target healthcare company by acquiring an additional 0.79% of its share capital, comprising 119,545 Series B preferred shares, for US$10 million. This follows its earli...
Shanghai INT Medical Instruments Starts Pre-Listing Tutoring for Potential A-Share Issue
Jun 12, 2026
Shanghai INT Medical Instruments Co., Ltd., a PRC-based medical device company listed in Hong Kong, plans to further expand its capital markets footprint by pursuing a potential A-share issuance on a stock exchange in mainland China. The move unde...
Shanghai INT Medical Completes Full Conversion to H Shares in Hong Kong
Jun 3, 2026
Shanghai INT Medical Instruments has completed the conversion of 71,786,608 domestic shares into H shares, making all 211,200,000 of its issued shares H shares listed in Hong Kong. The move unifies the company’s share capital structure offsh...
Shanghai INT Medical Sets Formal Remuneration Committee Mandate
May 29, 2026
Shanghai INT Medical Instruments has formalized detailed terms of reference for its board-level Remuneration Committee to strengthen its remuneration governance framework. The committee is structured to comprise a majority of independent non-execu...
Shanghai INT Medical Tightens Audit Committee Mandate to Bolster Governance and Risk Oversight
May 29, 2026
Shanghai INT Medical Instruments Co., Ltd. has formalized detailed terms of reference and procedures for its Board Audit Committee to strengthen internal control, audit oversight, and governance across the Group. The Committee is tasked with monit...
Shanghai INT Medical Sets Nomination Committee Rules to Strengthen Board Governance
May 29, 2026
Shanghai INT Medical Instruments has formally established a Nomination Committee under its board, defining its composition, authority and working procedures in line with PRC Company Law, the Hong Kong Listing Rules and the company’s Articles...
Shanghai INT Medical Instruments Shareholders Unanimously Back 2025 Results and Dividend Plan
May 28, 2026
Shanghai INT Medical Instruments Co., Ltd. held its 2025 annual general meeting in Shanghai on 28 May 2026, with all directors attending in person or electronically and meeting procedures confirmed as compliant with PRC Company Law and the firm...
Shanghai INT Medical Instruments Cancels Planned Broncus Share Subscription
May 26, 2026
Shanghai INT Medical Instruments Co., Ltd. announced that it has mutually agreed with Broncus Holding Corporation to terminate a planned subscription of 91,093,613 new Broncus shares, which had been valued at over HK$283 million. Under the termina...
Shanghai INT Medical Wins Approval for Major H-Share Conversion
May 13, 2026
Shanghai INT Medical Instruments Co., Ltd. has received approval from the Hong Kong Stock Exchange to list 71,786,608 converted H shares, which will be created through the conversion of an equivalent number of domestic shares held by 12 existing s...
Shanghai INT Medical to Acquire 23.18% Stake in Target Company for US$108 Million
May 12, 2026
Shanghai INT Medical Instruments Co., Ltd. has agreed to acquire a 23.18% equity stake in an unnamed target company for US$107.76 million, comprising a mix of ordinary and preferred shares. The acquisition price is equivalent to about RMB737.79 mi...
Shanghai INT Medical Instruments Wins CSRC Nod for H-Share Full Circulation Plan
May 11, 2026
Shanghai INT Medical Instruments has obtained a filing notice from the China Securities Regulatory Commission approving its application to convert 71,786,608 domestically held shares into H shares. The move, involving 12 existing shareholders, aim...
Shanghai INT Medical to Take Full Control of Pulin Medical via RMB31 Million Stake Purchase
Apr 29, 2026
Shanghai INT Medical Instruments Co., Ltd. has moved to consolidate its control over Pulin Medical, a key operating subsidiary, by acquiring the remaining 35% minority equity stake for a total consideration of RMB31.29 million. The transaction wil...
Shanghai INT Medical Moves to Acquire Valgen Medtech Stake to Bolster Heart Device Portfolio
Apr 28, 2026
Shanghai INT Medical Instruments Co., Ltd. plans to acquire up to 90% of Valgen Holding Corporation, parent of Hangzhou Valgen Medtech, for no more than RMB1.5 billion to deepen its presence in structural heart disease devices. Valgen Medtech spec...
Shanghai INT Medical Sets 2026 AGM to Approve Results, Budget and Share Buyback Mandate
Apr 22, 2026
Shanghai INT Medical Instruments Co., Ltd. has called its annual general meeting for 28 May 2026 in Shanghai, where shareholders will review reports from the board and supervisory committee, the 2025 annual report, audited group financial statemen...
Shanghai Kindly Medical Declares Final 2025 Dividend for H Shareholders
Mar 27, 2026
Shanghai Kindly Medical Instruments Co., Ltd. has declared a final ordinary cash dividend of RMB 0.23 per share for the financial year ended 31 December 2025, equivalent to HKD 0.26 per H share based on an exchange rate of RMB 1 to HKD 1.135. The ...
Shanghai Kindly Medical Posts Double-Digit Profit Growth on Rising Interventional Device Sales
Mar 27, 2026
Shanghai Kindly Medical Instruments Co., Ltd. reported strong growth for the year ended 31 December 2025, with revenue rising 25.06% year on year to RMB1.07 billion, driven by an expanded customer base and business combinations. Sales of intervent...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.